Major financial data for the past five years is posted.
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Sales |
77,748 |
90,101 |
107,547 |
120,025 |
145,419 |
|
Operating profit |
15,239 |
18,030 |
22,135 |
30,079 |
45,218 |
|
Operating profit margin (%) |
19.6 |
20.0 |
20.6 |
25.1 |
31.1 |
|
Ordinary income |
16,326 |
17,635 |
21,968 |
29,563 |
45,185 |
|
Net income |
10,857 |
13,106 |
15,808 |
12,737 |
32,075 |
|
Net assets |
121,130 |
134,300 |
151,961 |
151,354 |
174,358 |
|
Total assets |
155,127 |
172,644 |
191,614 |
193,187 |
218,285 |
|
Operating cash flow |
17,302 |
19,138 |
34,708 |
40,543 |
40,095 |
|
Investment cash flow |
-18,703 |
-15,135 |
-21,222 |
-13,434 |
-11,739 |
|
Free cash flow |
-1,401 |
4,003 |
13,486 |
27,109 |
28,356 |
|
Financial cash flow |
11,368 |
-2,342 |
-13,878 |
-8,107 |
-19,971 |
|
Depreciation |
6,439 |
7,513 |
8,464 |
9,190 |
8,799 |
|
R＆D expenses |
8,869 |
9,723 |
11,662 |
12,248 |
13,372 |
|
Employees: Consolidated (persons) |
10,435 |
10,187 |
9,371 |
9,473 |
10,177 |
|
Employees: Non-consolidated (persons) |
1,041 |
1,016 |
1,088 |
1,196 |
1,285 |
|
Number of shares issued and outstanding (shares) |
271,633,600 |
271,633,600 |
271,633,600 |
271,633,600 |
265,332,300 |
|
Net income per share (￥) |
40.01 |
48.25 |
58.20 |
46.92 |
120.59 |
|
Net assets per share (￥) |
439.80 |
487.12 |
556.71 |
558.31 |
653.57 |
|
ROE (Return On Equity) (%) |
10.2 |
10.4 |
11.2 |
8.4 |
19.8 |
|
ROIC (Return On Invested Capital) (%) |
10.9 |
10.7 |
12.1 |
13.1 |
18.5 |
|
Dividend (￥) |
11.99 |
14.48 |
20.37 |
24.23 |
48.24 |
|
Consolidated dividend payout ratio (%) |
30.0 |
30.0 |
35.0 |
35.0 |
35.0 |
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Sales |
77,748 |
90,101 |
107,547 |
120,025 |
145,419 |
|
Medical business |
68,345 |
78,552 |
95,654 |
107,779 |
126,798 |
|
Device business |
9,403 |
11,549 |
11,892 |
12,245 |
18,620 |
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Operating cash flow |
17,302 |
19,138 |
34,708 |
40,543 |
40,095 |
|
Investment cash flow |
-18,703 |
-15,135 |
-21,222 |
-13,434 |
-11,739 |
|
Free cash flow |
-1,401 |
4,003 |
13,486 |
27,109 |
28,356 |
|
Financial cash flow |
11,369 |
-2,342 |
-13,878 |
-8,107 |
-19,971 |
(￥ million)
|
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
Depreciation |
6,439 |
7,513 |
8,464 |
9,190 |
8,799 |
|
R＆D Expenses |
8,869 |
9,723 |
11,662 |
12,248 |
13,372 |
（％）
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
ROE (Return On Equity) |
10.2 |
10.4 |
11.2 |
8.4 |
19.8 |
|
ROIC (Return On Invested Capital) |
9.1 |
9.0 |
10.1 |
13.1 |
18.5 |
